BR112019018861A2 - Uso de nitrito de sódio, método para manter os níveis fisiológicos de nitrito, prevenir enfarte do miocárdio, prevenir morte súbita cardíaca, prevenir acidente vascular cerebral, doenças cardiovasculares, pressão alta, solução aquosa - Google Patents

Uso de nitrito de sódio, método para manter os níveis fisiológicos de nitrito, prevenir enfarte do miocárdio, prevenir morte súbita cardíaca, prevenir acidente vascular cerebral, doenças cardiovasculares, pressão alta, solução aquosa

Info

Publication number
BR112019018861A2
BR112019018861A2 BR112019018861A BR112019018861A BR112019018861A2 BR 112019018861 A2 BR112019018861 A2 BR 112019018861A2 BR 112019018861 A BR112019018861 A BR 112019018861A BR 112019018861 A BR112019018861 A BR 112019018861A BR 112019018861 A2 BR112019018861 A2 BR 112019018861A2
Authority
BR
Brazil
Prior art keywords
prevent
nitrite
aqueous solution
myocardial infarction
sudden cardiac
Prior art date
Application number
BR112019018861A
Other languages
English (en)
Portuguese (pt)
Inventor
Craig Sherman
Original Assignee
Hope Medical Entpr Inc Dba Hope Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hope Medical Entpr Inc Dba Hope Pharmaceuticals filed Critical Hope Medical Entpr Inc Dba Hope Pharmaceuticals
Publication of BR112019018861A2 publication Critical patent/BR112019018861A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1654—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1654—Dialysates therefor
    • A61M1/1656—Apparatus for preparing dialysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • External Artificial Organs (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112019018861A 2017-03-08 2018-03-06 Uso de nitrito de sódio, método para manter os níveis fisiológicos de nitrito, prevenir enfarte do miocárdio, prevenir morte súbita cardíaca, prevenir acidente vascular cerebral, doenças cardiovasculares, pressão alta, solução aquosa BR112019018861A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762468857P 2017-03-08 2017-03-08
PCT/US2018/021053 WO2018165098A1 (en) 2017-03-08 2018-03-06 Intradialytic use of sodium nitrite

Publications (1)

Publication Number Publication Date
BR112019018861A2 true BR112019018861A2 (pt) 2023-10-10

Family

ID=63445965

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019018861A BR112019018861A2 (pt) 2017-03-08 2018-03-06 Uso de nitrito de sódio, método para manter os níveis fisiológicos de nitrito, prevenir enfarte do miocárdio, prevenir morte súbita cardíaca, prevenir acidente vascular cerebral, doenças cardiovasculares, pressão alta, solução aquosa

Country Status (15)

Country Link
US (5) US10328099B2 (enExample)
EP (2) EP3592342B1 (enExample)
JP (3) JP7314050B2 (enExample)
KR (4) KR102647803B1 (enExample)
AR (1) AR111166A1 (enExample)
AU (2) AU2018231016B2 (enExample)
BR (1) BR112019018861A2 (enExample)
CA (1) CA3055105A1 (enExample)
ES (1) ES2986444T3 (enExample)
IL (4) IL301302B2 (enExample)
NZ (1) NZ756701A (enExample)
PH (1) PH12019501950A1 (enExample)
TW (3) TWI798203B (enExample)
WO (1) WO2018165098A1 (enExample)
ZA (3) ZA201905679B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301302B2 (en) 2017-03-08 2024-09-01 Hope Medical Entpr Inc Dba Hope Pharmaceuticals Intradialytic use of sodium nitrite
ES2992792T3 (en) 2017-03-08 2024-12-18 Hope Medical Entpr Inc D B A Hope Pharmaceuticals Intradialytic use of sodium thiosulfate
KR102875863B1 (ko) * 2019-07-22 2025-10-23 스쿨 주리디칼 퍼슨 키타사토 인스티튜트 투석 장치
US20230149732A1 (en) * 2021-11-17 2023-05-18 Wake Forest University Health Sciences Combined nitrite and light treatment to prevent device thrombosis
US12128166B2 (en) 2022-12-16 2024-10-29 Fresenius Medical Care Holdings, Inc. Systems and methods for using nitric oxide in dialysis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341151C (en) 1985-09-10 2000-12-05 Elias Klein Osmotic agents form peritoneal dialysis
US6380163B1 (en) 1992-12-22 2002-04-30 Baxter International Inc. Peritoneal dialysis solutions with polypeptides
FI98538C (fi) 1993-10-20 1997-07-10 Enso Gutzeit Oy Menetelmä natriumhydroksidin valmistamiseksi valkolipeästä
US6306836B1 (en) 1994-01-21 2001-10-23 Baxter International Inc. Peritoneal dialysis solutions containing maltodextrins and amino acids
US6436969B1 (en) 1995-09-12 2002-08-20 Kansas University Medical Center Research Institute Inc. Dialysis solutions and methods
JP4882054B2 (ja) 2000-09-13 2012-02-22 独立行政法人科学技術振興機構 腹膜透析液およびその調製法
CA2537222A1 (en) * 2003-07-09 2005-01-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
US7362274B1 (en) * 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
US20070154570A1 (en) * 2004-09-29 2007-07-05 Miller Christopher C Use of nitric oxide in the treatment and disinfection of biofilms
US7547637B2 (en) * 2005-06-21 2009-06-16 Intel Corporation Methods for patterning a semiconductor film
US20090304600A1 (en) 2008-06-09 2009-12-10 Anupkumar Shetty Intradialytic administration of sodium thiosulfate
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
DK2451435T4 (da) 2009-07-08 2022-02-28 Hope Medical Entpr Inc D B A Hope Pharmaceuticals Natriumthiosulfat-indeholdende farmaceutiske sammensætninger
WO2013023217A1 (en) * 2011-08-11 2013-02-14 Board Of Regents, The University Of Texas System Method of measuring and monitoring in vivo nitrite levels
AU2013212264B2 (en) 2012-01-23 2017-05-18 Santalis Pharmaceuticals Inc. Sandalwood oil and its uses related to clostridium infections
JP5486069B1 (ja) 2012-11-05 2014-05-07 旭 酒井 透析装置
US20140350097A1 (en) 2013-05-23 2014-11-27 Medinox,Inc. Treatment of hypotension associated with hemodialysis
JP6183832B2 (ja) 2013-06-19 2017-08-23 扶桑薬品工業株式会社 酸化ストレス抑制型透析用剤およびその調製方法
IL301302B2 (en) 2017-03-08 2024-09-01 Hope Medical Entpr Inc Dba Hope Pharmaceuticals Intradialytic use of sodium nitrite

Also Published As

Publication number Publication date
KR20250017763A (ko) 2025-02-04
CA3055105A1 (en) 2018-09-13
KR102760913B1 (ko) 2025-02-03
EP3592342A4 (en) 2020-12-23
JP2020510014A (ja) 2020-04-02
ES2986444T3 (es) 2024-11-11
AU2018231016B2 (en) 2024-03-07
IL284684B2 (en) 2023-08-01
IL301302A (en) 2023-05-01
US20190255098A1 (en) 2019-08-22
EP4406595A3 (en) 2024-10-30
IL312092B1 (en) 2025-04-01
KR20190130588A (ko) 2019-11-22
EP3592342A1 (en) 2020-01-15
TW201836594A (zh) 2018-10-16
US11564938B2 (en) 2023-01-31
IL301302B1 (en) 2024-05-01
JP2024174935A (ja) 2024-12-17
US20210077524A1 (en) 2021-03-18
PH12019501950A1 (en) 2020-06-15
JP2023134621A (ja) 2023-09-27
KR102647803B1 (ko) 2024-03-15
TWI835595B (zh) 2024-03-11
IL312092A (en) 2024-06-01
ZA201905679B (en) 2023-02-22
EP3592342B1 (en) 2024-06-19
NZ756701A (en) 2022-07-01
JP7765687B2 (ja) 2025-11-07
ZA202208504B (en) 2024-01-31
TW202325265A (zh) 2023-07-01
AU2018231016A1 (en) 2019-09-19
AU2024203535A1 (en) 2024-06-20
JP7314050B2 (ja) 2023-07-25
TW202421096A (zh) 2024-06-01
ZA202307367B (en) 2024-11-27
IL268882B (en) 2021-07-29
KR102706379B1 (ko) 2024-09-19
US20180256637A1 (en) 2018-09-13
IL312092B2 (en) 2025-08-01
IL268882A (en) 2019-10-31
KR20240038812A (ko) 2024-03-25
US10328099B2 (en) 2019-06-25
TWI798203B (zh) 2023-04-11
IL284684A (en) 2021-08-31
JP7551858B2 (ja) 2024-09-17
WO2018165098A1 (en) 2018-09-13
TWI888012B (zh) 2025-06-21
IL284684B1 (en) 2023-04-01
KR20240137711A (ko) 2024-09-20
AR111166A1 (es) 2019-06-12
US10898512B2 (en) 2021-01-26
US20240285677A1 (en) 2024-08-29
EP4406595A2 (en) 2024-07-31
US12011456B2 (en) 2024-06-18
US20230256005A1 (en) 2023-08-17
IL301302B2 (en) 2024-09-01

Similar Documents

Publication Publication Date Title
BR112019018861A2 (pt) Uso de nitrito de sódio, método para manter os níveis fisiológicos de nitrito, prevenir enfarte do miocárdio, prevenir morte súbita cardíaca, prevenir acidente vascular cerebral, doenças cardiovasculares, pressão alta, solução aquosa
MX2024010140A (es) Nuevos metodos.
AR071810A1 (es) Metodo de tratamiento de la disnea asociada con la insuficiencia cardiaca aguda. relaxina h2. uso.
MX382520B (es) Compuestos de pirimidinodiona contra estados cardiacos.
GB2540638A8 (en) Compositions, Formulations and methods for treating ocular diseases
BR112017017888A2 (pt) derivados fluorados do ácido tetraidronaftiridinil nonanoico derivados e usos destes
GEP20207095B (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
CL2021001389A1 (es) Formulaciones en cápsula
AR103415A1 (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2
BR112015004643A2 (pt) métodos e composições para ressucitação hipotensiva
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
ZA202209104B (en) Intradialytic use of sodium thiosulfate
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
MX2015014939A (es) Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension.
BR112015024897A2 (pt) derivado de fenila
BR112017000052A2 (pt) solução cardioplégica de uso geral (variantes)
RU2015133365A (ru) Альфа-2 адренергический агонист для лечения внутриглазного давления и заболеваний глаз путем введения в стекловидное тело и внутрикамерно
EP4529951A3 (en) Methods for decreasing injuries associated with intraoperative hypotension
Altin IgE-mediated allergic angioedema in an elderly patient: case report
UA94690U (en) Method of preparation the patients with concomitant coronary heart disease to video thoracoscopic operations
Akgullu Myocardial infarction secondary to Kounis Syndrome: case report
MX2016001113A (es) Proceso y composicion farmaceutica de obtencion de una capsula de telmisartan e hidroclorotiazida por via humeda.
Athar Dobutamine/norepinephrine
Ahmed et al. Late stent fracture-A potential role of left ventricular dilatation
Ferrera Myopathy: case report

Legal Events

Date Code Title Description
B12F Other appeals [chapter 12.6 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]